JP2004518740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004518740A5 JP2004518740A5 JP2002565962A JP2002565962A JP2004518740A5 JP 2004518740 A5 JP2004518740 A5 JP 2004518740A5 JP 2002565962 A JP2002565962 A JP 2002565962A JP 2002565962 A JP2002565962 A JP 2002565962A JP 2004518740 A5 JP2004518740 A5 JP 2004518740A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- compound
- halogen
- embedded image
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 description 90
- 239000001257 hydrogen Substances 0.000 description 90
- 150000001875 compounds Chemical class 0.000 description 70
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 46
- 150000002431 hydrogen Chemical class 0.000 description 44
- 229910052736 halogen Inorganic materials 0.000 description 34
- 150000002367 halogens Chemical class 0.000 description 34
- -1 C 1 -C 6 alkyl Chemical class 0.000 description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 208000015114 central nervous system disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- IKQCKANHUYSABG-ZKCHVHJHSA-N CC[C@H]1CC[C@H](N)CC1 Chemical compound CC[C@H]1CC[C@H](N)CC1 IKQCKANHUYSABG-ZKCHVHJHSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 2
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- KSMVBYPXNKCPAJ-LJGSYFOKSA-N C[C@H]1CC[C@H](N)CC1 Chemical compound C[C@H]1CC[C@H](N)CC1 KSMVBYPXNKCPAJ-LJGSYFOKSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- GKWPVNAPLMRNCD-SMDDNHRTSA-N (1r,2r)-2-[[4-[6-(trifluoromethyl)-1-benzothiophen-3-yl]piperazin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@@H]1C[C@H]1CN1CCN(C=2C3=CC=C(C=C3SC=2)C(F)(F)F)CC1 GKWPVNAPLMRNCD-SMDDNHRTSA-N 0.000 description 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
- PINAYRGSNKSMKY-UHFFFAOYSA-N 1-[2-[4-[6-(trifluoromethyl)-1-benzothiophen-3-yl]piperazin-1-yl]ethyl]cyclopropane-1-carboxylic acid Chemical compound C1CN(C=2C3=CC=C(C=C3SC=2)C(F)(F)F)CCN1CCC1(C(=O)O)CC1 PINAYRGSNKSMKY-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 201000006152 substance dependence Diseases 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26967201P | 2001-02-16 | 2001-02-16 | |
| GBGB0117577.7A GB0117577D0 (en) | 2001-02-16 | 2001-07-19 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands |
| PCT/US2002/004713 WO2002066446A1 (en) | 2001-02-16 | 2002-02-15 | Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009097547A Division JP2009185054A (ja) | 2001-02-16 | 2009-04-14 | 複素環置換カルボニル誘導体およびドーパミンｄ３受容体リガンドとしてのその使用 |
| JP2009097550A Division JP2009185055A (ja) | 2001-02-16 | 2009-04-14 | 複素環置換カルボニル誘導体およびドーパミンｄ３受容体リガンドとしてのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004518740A JP2004518740A (ja) | 2004-06-24 |
| JP2004518740A5 true JP2004518740A5 (enExample) | 2010-08-19 |
| JP4685331B2 JP4685331B2 (ja) | 2011-05-18 |
Family
ID=23028219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565962A Expired - Fee Related JP4685331B2 (ja) | 2001-02-16 | 2002-02-15 | 複素環置換カルボニル誘導体およびドーパミンｄ３受容体リガンドとしてのその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7186724B2 (enExample) |
| JP (1) | JP4685331B2 (enExample) |
| CO (1) | CO5370677A1 (enExample) |
| DE (1) | DE60229673D1 (enExample) |
| GB (1) | GB0117577D0 (enExample) |
| PA (1) | PA8540001A1 (enExample) |
| UY (1) | UY27179A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2438318A1 (en) * | 2001-02-16 | 2002-08-29 | Aventis Pharmaceuticals Inc. | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands |
| US7880001B2 (en) * | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US8415354B2 (en) * | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US8198331B2 (en) * | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| KR101496190B1 (ko) | 2005-01-05 | 2015-02-26 | 애브비 인코포레이티드 | 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체 |
| US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| ATE461925T1 (de) * | 2005-04-26 | 2010-04-15 | Hypnion Inc | Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung |
| BRPI0611370A2 (pt) * | 2005-05-23 | 2010-08-31 | Sagami Chem Res | derivados de pirazol-1-carboxilato, processos para a producão destes e processos para a producão de derivados de pirazol |
| KR101062513B1 (ko) * | 2006-02-17 | 2011-09-06 | 에프. 호프만-라 로슈 아게 | 5ｈｔ2/ｄ3 조절제로서의 벤조일-피페리딘 유도체 |
| US7435833B2 (en) * | 2006-04-07 | 2008-10-14 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| EP2074105A4 (en) * | 2006-10-13 | 2010-10-06 | Neuromed Pharmaceuticals Ltd | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM INHIBITORS |
| ES2498673T3 (es) * | 2007-07-26 | 2014-09-25 | F. Hoffmann-La Roche Ag | Moduladores duales de los receptores 5-HT2a y D3 |
| JP5736098B2 (ja) * | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
| FR2953836B1 (fr) * | 2009-12-14 | 2012-03-16 | Sanofi Aventis | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
| FR2953839A1 (fr) * | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
| US8877778B2 (en) * | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| US8921397B2 (en) * | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
| WO2014026330A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| NZ726874A (en) * | 2014-05-19 | 2018-03-23 | Merial Inc | Anthelmintic compounds |
| CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
| EP3368516B1 (en) | 2015-10-27 | 2020-07-15 | Merck Sharp & Dohme Corp. | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| US10287272B2 (en) | 2015-10-27 | 2019-05-14 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as RORgammaT inhibitors and uses thereof |
| JP2018531958A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用 |
| CN115572218B (zh) * | 2022-08-29 | 2024-04-16 | 江阴勒森生物科技有限公司 | 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US354411A (en) | 1886-12-14 | Castle | ||
| US5116970A (en) * | 1988-02-18 | 1992-05-26 | New James S | Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones |
| IL94151A (en) * | 1989-04-22 | 1995-08-31 | Wyeth John & Brother Ltd | History of piperazine, their preparation and pharmaceutical preparations containing them |
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| FR2680366B1 (fr) * | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| ES2139750T3 (es) * | 1993-08-06 | 2000-02-16 | Upjohn Co | 2-aminoindanos como ligandos selectivos d3 de la dopamina. |
| DE4425146A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
| JP3421682B2 (ja) * | 1995-01-26 | 2003-06-30 | 株式会社アイジー技術研究所 | 役物下型材 |
| JPH10152470A (ja) * | 1996-09-25 | 1998-06-09 | Yoshitomi Pharmaceut Ind Ltd | ピペラジン化合物 |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| GB9821978D0 (en) | 1998-10-08 | 1998-12-02 | Smithkline Beecham Plc | Compounds |
| CZ20022603A3 (cs) * | 1999-12-30 | 2002-10-16 | H. Lundbeck A/S | 4-fenyl-1-piperazinylové deriváty |
| SK1092003A3 (en) * | 2000-06-29 | 2003-05-02 | Lundbeck & Co As H | Indole derivatives useful for the treatment of CNS disorders |
| GB0117950D0 (en) * | 2001-02-16 | 2001-09-19 | Aventis Pharma Inc | Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands |
-
2001
- 2001-07-19 GB GBGB0117577.7A patent/GB0117577D0/en not_active Ceased
-
2002
- 2002-02-15 CO CO02013028A patent/CO5370677A1/es not_active Application Discontinuation
- 2002-02-15 JP JP2002565962A patent/JP4685331B2/ja not_active Expired - Fee Related
- 2002-02-15 DE DE60229673T patent/DE60229673D1/de not_active Expired - Lifetime
- 2002-02-18 PA PA20028540001A patent/PA8540001A1/es unknown
- 2002-02-18 UY UY27179A patent/UY27179A1/es unknown
-
2004
- 2004-04-06 US US10/819,037 patent/US7186724B2/en not_active Expired - Fee Related
-
2007
- 2007-03-05 US US11/714,047 patent/US7521445B2/en not_active Expired - Fee Related
-
2009
- 2009-04-17 US US12/425,731 patent/US7772252B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4139325B2 (ja) | ミクロソーム・トリグリセリド・トランスファータンパク質（ｍｔｐ）及び／又はアポリポタンパク質ｂ（ａｐｏｂ）分泌の阻害剤としてのトリアミド置換インドール、ベンゾフラン及びベンゾチオフェン | |
| JP4787254B2 (ja) | インドール、インダゾールまたはインドリン誘導体 | |
| JP5049267B2 (ja) | ベンズイソオキサゾールピペラジン化合物およびその使用方法 | |
| JPH08510736A (ja) | 炎症治療用置換オキサゾリル化合物 | |
| RU2501794C2 (ru) | Активирующий агент для рецептора, активируемого стимулирующими рост пероксисом агентами | |
| US20070021606A1 (en) | Therapeutic compounds | |
| RU2005115115A (ru) | 4-пиперазинилбензолсульфонилиндолы, характеризующиеся сродством к рецептору 5-нт6 | |
| JPH10508870A (ja) | カンナビノイド受容体への親和性を有するインドール誘導体 | |
| JP2004524301A5 (enExample) | ||
| JP2004525951A5 (enExample) | ||
| JP2002030084A5 (enExample) | ||
| JP2010525024A (ja) | 置換３−（４−ヒドロキシフェニル）−インドリン−２−オン化合物 | |
| RU2003115426A (ru) | Замещенные производные 2-фениламиноимидазолинфенилкетона в качестве антагонистов ip | |
| JP2005500345A5 (enExample) | ||
| ES2210028T3 (es) | Nuevos compuestos. | |
| JP2008534572A5 (enExample) | ||
| CA2580024A1 (en) | Therapeutic diphenyl ether ligands | |
| JP2010513489A5 (enExample) | ||
| JP2008542365A5 (enExample) | ||
| JP2722586B2 (ja) | インドリルイミダゾール誘導体 | |
| CN101291912A (zh) | 吡唑衍生物、含有此类化合物的组合物及其使用方法 | |
| JPH09505820A (ja) | Ｎ置換アザビシクロヘプタン誘導体、例えば神経弛緩剤 | |
| JP2004522781A5 (enExample) | ||
| CN101553467A (zh) | 5-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途 | |
| JPH02138214A (ja) | 不安を治療する方法 |